Onkimmune believes that the combination of a potent NK cell, with strategies to further enhance its targeting, and the addition of a further patented killing mechanism in TRAIL, to enhance its efficacy in killing tumour cells, would be a very attractive product for major pharmaceutical companies.
Onkimmune ONK cell approach provides a low cost, safe, effective, off‐the‐shelf, dose titratable solution that makes cell therapy more accessible.
- Broad patient applicability, low/no CRS risk, no uncontrolled expansion
- Use like a drug (short half life)
- High cancer killing ability
- Batch manufacture in hours, easy distribution, low cost
At the present time, the leading cellular immunotherapy candidates to progress to drug approval are based on human T-cells, which are modified with the addition of Chimeric Antigen Receptors (CARs) forming CAR T cells which can then recognise and destroy cancer cells.
However, despite the fantastic responses seen with CAR-T cells, they have a number of disadvantages relating to safety, manufacturing, cost and delivery, and may not be appropriate for all patients
Given the potential side effects of T-cell therapy, utilizing an alternative type of immune cell, i.e. NK cells, could provide a more ideal solution. NK cells have the potential to be, more effective, safer and more amenable to development as an off-the-shelf therapy, are easier to manufacture and have lower production costs.